Previous studies ha ve evaluated the effe cts of como rbidity on survival in patient s with cance r. We app lied the Charlson comorbidity index (CCl) to a coho rt ofpatients with laryngeal cance r to validate its use and to assess the prognosti c impact of age . Our study p opulation consisted of 152 patients with laryngeal cance r who we re see n ove r a JO-yearperiod. Patient s we re ass igned CCl sco res and were catego rized into low-and high -grade como rbidity groups fo r comparison. Age adjustm ents we re p erformed by adding 1 p oint to the Charl son sco re f or each decad e ove r the median age.
Introduction
Cancer is primarily a disease of the elderl y.J With most cancers, incidence and mortality incre ase with age.' Re- ' cent report s have que stioned whether or not age and comorbid conditions should be con sidered as part of the staging system, since both are significant progno stic indicators. ' Staging has long been accepted as the best single determin ant of survival in patients with laryngeal cancer.' However, recent reports suggest that including other clinical variables such as comorbid conditions can improve the prediction of survival in patients with head and neck cancer.t" Elderl y patient s are more likely to have comorbidities such as cardio vascular disease, pulmon ary disease, and renal insufficiency .' Previou s studies have suggested that age and comorb idity are independent predictor s of survival." Age is an important predictor for the risk of death attributable to comorbid disease."Therefore, it is logical to combine age and comorbidity into a prognostic staging system. The Charlson comorbidity index (CCI) was found to be a good progno stic indicator in patients with head or neck cancer.v? However, no studies have applied the CCI to a cohort of patient s whose head or neck cancer was confined to a single anatomic location. The current study was performed to validate the prognostic abilit y of the CCI for tumor-specific survival in patients with laryngeal cancer. Age was added as a comorbid conditi on in an attempt to determin e whether or not it improves the prognostic ability of the CCI.
Materials and meth ods
Our study population was drawn from two hospitals in Brooklyn , N.Y. (Kings County Hospital Center and the Long Island College Hospital) durin g the 1O-yearperiod between January 1984 and Febru ary 1994. Data were obtained from medical record s, tumor registry abstracts, and pathology reports and supplemented by direct patient cont act. Only patients who had biopsy -proven squamous cell carcinoma of the larynx were included in the study. We reviewed eac h patient's demo graphic data , the type ENT-Ear, Nose & Throat Jo ur nal s A ugust 1999 Athree-part regimen: Salagerr Tablets, tailored dosage and time.
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Results
The study popul ation consisted of 114 men and 38 women. (table 2) , patients with a high comorbidity index had poorer survival than patients with a low level of comorbidity (p =0.002). High como rbidity carried a relative risk of 1.57 for death (95% confidence interval: 1.1 8 to 2.08).There were no differences in survival based on tobacco or alcohol use, gender distribution by pathologic grade, treatment modality, or the mean time to recurrence. There was no difference in the rate or severity of complications based on the comorbidity gra de. ---,.--...,---,-----,.--...,---,-----,.--....,-. and intent of treatment (ie, curative or palliati ve), pathologic gradi ng and staging, the incidence and severity of complications, and treatm ent outcomes. Eac h patient was eva luated by the CC I based on the admitting history, medica l cle arance for cancer trea tme nt, preo pera tive anesthesia evaluation, and/or med ical eva luations wit hin 6 mo nths of the initia l prese nta tion with cancer. Th e total CCI sco re was determined by adding the weighted score of eac h co mor bid condi tion . CCI gra des 1, 2, 3, and 4 were esta blishe d for scores of 0, 1-2, 3-4 , and~5 , respec tive ly. The age -adjusted co mor bidity inde x was ca lculated by adding I point to the CCI for eac h decade of age ove r the median of the popul ation. Grades I and 2 were classified as low-grade como rbidity , and grades 3 and 4 were co nsidere d high-grade. The CC I and the age-adj usted CCI were co mpare d for prog nostic ability.
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Tum or stage was determ ined by rev iewing tum or maps and opera tive reports, and was based on the criteria established in 1992 by the American Joint Committee on Cancer. 10 Out come was determ ined by assessing the presence or abse nce of cancer at the time of the last con tact and the patien t' s curre nt status (alive , dead, or unknown ). For patients who died, the ca use was determined from dea th cer tificates, surgeo ns' reco rds , fam ily contacts, or tumor registr y abstracts.
Tum or-specific survival was defined as the period of time between the first day of treatm ent and the day of the last followup . Sur vival analyses was based on surviva l until study co mpletio n, the duration of followup, or death. The date and location of the first recurrence were also docum ent ed. The prognostic ability of the co morbidity indices were compared to the TNM staging sys tem for tumor-specific survival.
Statistica l significance was defined as a two-tailed p value less than or equal to 0.05. Fisher' s Exact Test was performed for exac t nonp aram etric inference. All other analyses, including survival functions, were performed with the True Epistat software package for med ica l statistics . Survival curves were estimated by Kaplan-Meie r (product limit) analysis to allow for the maximum use of censore d observations. (Ce nsored subjects were those who either survived to the end of the study, we re lost to followup durin g the study, or died of a cause unrel ated to the cancer.) Survival co mpariso ns were perform ed w ith th e ge nera lize d Wilcoxo n's test, a distributi on-free vival. However, the CC I was more easily app lied. In this study , the CC I was successfully app lied to a cohort of patients with laryngeal ca ncer. T umor stagi ng did not predict survival unt il the confoundi ng effects of comorbidity were co nsi dered (co morbidity entai led medical illnesses only) . Standard cancer treatm en t plans do not emphasize the confounding effects of comorbidity on surv ival. Before a treatment pla n is chosen for a patien t d iagnosed wit h cancer, the disease is assessed on the bas is of tumor size, no da l disease, and metastasis, and the prog nosis is based on this classification scheme. By fac toring comorbidity into the initial staging, the physician can make a more accurate pre diction of survival.
By assessing a pat ien t's medical history and examination , the process of assigning a CC I score is sim ple. . Patients ca n be placed into either a low-or high -grade comorbidity group . T umor-specific survival ca n be predicted after de termi ning the co mor bidity gra de . Charlson suggested tha t with longitud inal stu dies , both age and comorbidity sho uld be taken into account as predictors of death." Older patients have more overall comorbidity. By adding age to the co morbidi ty index, we were able to reclassify 18% of our patients from low-to high-grade comorbidi ty. Even so, incorporating age as an High co morbidity age as a co morbid co ndi tion led (re lative to low) us to reclassify 18% of our patients from the low-to the hig h-Tumor sta ge como rbidity gro up. Consequent-(relative to the mean) Iy, the age-adjusted CCI survival fell fro m a re lative risk of 1.57 before age adj ustment to 1.36 afterward. The high comorbidity seen in the elderly patients was not an age-depe ndent reason for lower tumor-specific surviva l.
Discussion
Th e TNM classification scheme is a useful system to describe tum or charac teris tic s and predict survival. However, TNM does not take into account im portant patientre lated fac tors such as the host ' s functional sta tus, comorbidities, immunocom petence, and symptom severity .II.12 Weymuller has suggested tha t comorbid conditions be incl uded among the prognostic variables in multiins titutio nal trials. "
T wo comorbidity indices have previously bee n validated for use in head and neck ca ncer for assessing the impact of comorbid conditions by number and severity. Previous studies have show n that the Kaplan-Feinstein co morbi dity index predicts survival in patients with laryngea l cancer.' However, the Charlson comorbidity index has not been previously app lied to a cohort ofpatients with laryngeal ca ncer. Singh et al compared the CC I to the Kap lan -Feins tein index in a co hort of patients younge r than 45 who had head or neck ca ncer. " Bo th indices were found to be prognostic indicators of tumor-specific sur- For more information Circle 109 on Reade r Service Card additional co morbid conditi on did not improve the prognostic ability of the CCL In co nclusion, this study suggests that the CCI is an independent pred ictor of tumorspecific survival. Com orbidity may serve as an indicator of the host ' s immunologic status." Thi s further support s the concept that co mor bidity may have an imp act on the behavior of the tum or , Furth er studies are nece ssary to confirm the influen ce of co mor bidity on surv ival, and to co mbine its effects with the TNM stag ing system for a more accurate predicti on of survival.
